Neubase Therapeutics Stock Price To Earnings To Growth

NBSE Stock  USD 0.44  0.02  4.76%   
NeuBase Therapeutics fundamentals help investors to digest information that contributes to NeuBase Therapeutics' financial success or failures. It also enables traders to predict the movement of NeuBase Stock. The fundamental analysis module provides a way to measure NeuBase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeuBase Therapeutics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NeuBase Therapeutics Company Price To Earnings To Growth Analysis

NeuBase Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

Current NeuBase Therapeutics Price To Earnings To Growth

    
  (0.07) X  
Most of NeuBase Therapeutics' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeuBase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

NeuBase Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for NeuBase Therapeutics is extremely important. It helps to project a fair market value of NeuBase Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since NeuBase Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NeuBase Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NeuBase Therapeutics' interrelated accounts and indicators.
0.93-0.93-0.440.390.060.760.940.59-0.41-0.41-0.060.8-0.270.170.60.560.390.70.73-0.25-0.37
0.93-0.91-0.320.380.290.530.860.33-0.38-0.380.090.75-0.110.340.350.420.230.670.660.08-0.22
-0.93-0.910.21-0.35-0.08-0.6-0.98-0.480.360.360.19-0.910.39-0.21-0.52-0.59-0.45-0.79-0.850.130.49
-0.44-0.320.21-0.46-0.12-0.57-0.3-0.510.490.480.02-0.07-0.22-0.23-0.47-0.31-0.430.01-0.150.240.11
0.390.38-0.35-0.460.320.270.330.14-0.99-0.990.230.150.020.280.130.170.240.030.14-0.01-0.2
0.060.29-0.08-0.120.32-0.080.03-0.13-0.33-0.330.160.060.110.19-0.130.21-0.01-0.040.010.540.07
0.760.53-0.6-0.570.27-0.080.740.93-0.33-0.33-0.360.62-0.54-0.270.920.780.580.50.66-0.57-0.55
0.940.86-0.98-0.30.330.030.740.67-0.36-0.35-0.310.94-0.50.070.690.710.560.790.9-0.26-0.57
0.590.33-0.48-0.510.14-0.130.930.67-0.21-0.2-0.590.63-0.65-0.380.990.830.730.440.68-0.61-0.65
-0.41-0.380.360.49-0.99-0.33-0.33-0.36-0.211.0-0.19-0.180.03-0.24-0.2-0.23-0.29-0.05-0.170.10.24
-0.41-0.380.360.48-0.99-0.33-0.33-0.35-0.21.0-0.19-0.170.03-0.23-0.2-0.23-0.29-0.04-0.170.10.24
-0.060.090.190.020.230.16-0.36-0.31-0.59-0.19-0.19-0.440.690.3-0.58-0.65-0.73-0.22-0.530.290.72
0.80.75-0.91-0.070.150.060.620.940.63-0.18-0.17-0.44-0.63-0.080.680.70.540.830.93-0.17-0.57
-0.27-0.110.39-0.220.020.11-0.54-0.5-0.650.030.030.69-0.630.57-0.67-0.76-0.62-0.38-0.640.370.81
0.170.34-0.21-0.230.280.19-0.270.07-0.38-0.24-0.230.3-0.080.57-0.42-0.26-0.05-0.12-0.120.340.09
0.60.35-0.52-0.470.13-0.130.920.690.99-0.2-0.2-0.580.68-0.67-0.420.830.720.50.72-0.59-0.63
0.560.42-0.59-0.310.170.210.780.710.83-0.23-0.23-0.650.7-0.76-0.260.830.760.460.76-0.32-0.82
0.390.23-0.45-0.430.24-0.010.580.560.73-0.29-0.29-0.730.54-0.62-0.050.720.760.190.62-0.37-0.87
0.70.67-0.790.010.03-0.040.50.790.44-0.05-0.04-0.220.83-0.38-0.120.50.460.190.88-0.12-0.22
0.730.66-0.85-0.150.140.010.660.90.68-0.17-0.17-0.530.93-0.64-0.120.720.760.620.88-0.21-0.61
-0.250.080.130.24-0.010.54-0.57-0.26-0.610.10.10.29-0.170.370.34-0.59-0.32-0.37-0.12-0.210.4
-0.37-0.220.490.11-0.20.07-0.55-0.57-0.650.240.240.72-0.570.810.09-0.63-0.82-0.87-0.22-0.610.4
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition

NeuBase Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(2.19)

At present, NeuBase Therapeutics' Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Based on the latest financial disclosure, NeuBase Therapeutics has a Price To Earnings To Growth of -0.07 times. This is 109.86% lower than that of the Biotechnology sector and 102.23% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 101.43% higher than that of the company.

Did you try this?

Run Watchlist Optimization Now

   

Watchlist Optimization

Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
All  Next Launch Module

NeuBase Fundamentals

About NeuBase Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NeuBase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NeuBase Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NeuBase Therapeutics' short interest history, or implied volatility extrapolated from NeuBase Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether NeuBase Therapeutics is a strong investment it is important to analyze NeuBase Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact NeuBase Therapeutics' future performance. For an informed investment choice regarding NeuBase Stock, refer to the following important reports:
Check out NeuBase Therapeutics Piotroski F Score and NeuBase Therapeutics Altman Z Score analysis.
For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for NeuBase Stock analysis

When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Stocks Directory
Find actively traded stocks across global markets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(18.60)
Return On Assets
(0.43)
Return On Equity
(0.93)
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.